title: Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.
abstract: Chronic lymphocytic leukemia (CLL), a proliferative disease of mature looking B lymphocytes, is the commonest leukemia in western countries. It remains incurable by available treatment modalities. We report on the establishment of a permanent, EBV-negative, B-CLL line (WSU-CLL) from the peripheral blood of a patient with CLL. The cells grow as suspension in liquid culture, express IgG lambda and other B cell markers and show lg heavy and light gene rearrangements. Karyotypic analysis shows 45,X,del(3)(p14;p24),t(4;12;12) (q31;q22;p13), t(5;12) (q31;p13), add(16)(q24)X2, t(18;21) (q12;p12). WSU-CLL forms colonies when grown on soft agar. A xenograft model was established by injecting the WSU-CLL cells subcutaneously (s.c.) in severe combined immune deficient (SCID) mice. When the s.c. tumor was transplanted in vivo to other SCID mice, the success rate was 100% with a doubling time of 7.3 days. The CLL-SCID xenograft model was used to test the efficacy of selected standard chemotherapy drugs and new therapeutic agents against WSU-CLL. The cell line and the xenograft described can be used as a model to facilitate the development of new therapeutic agents against CLL in man.
authors.affiliation: Department of Internal Medicine, Wayne State University School of Medicine, Detroit, MI 48201, USA.
authors.forename: R M
authors.initials: RM
authors.lastname: Mohammad
authors.forename: A N
authors.initials: AN
authors.lastname: Mohamed
authors.forename: M Y
authors.initials: MY
authors.lastname: Hamdan
authors.forename: T
authors.initials: T
authors.lastname: Vo
authors.forename: B
authors.initials: B
authors.lastname: Chen
authors.forename: K
authors.initials: K
authors.lastname: Katato
authors.forename: Y A
authors.initials: YA
authors.lastname: Abubakr
authors.forename: M C
authors.initials: MC
authors.lastname: Dugan
authors.forename: A
authors.initials: A
authors.lastname: al-Katib
mesh_terms: D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002869:Chromosome Aberrations; D004195:Disease Models, Animal; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D016130:Immunophenotyping; D007621:Karyotyping; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics / Q000473:pathology*; D008297:Male; D051379:Mice; D016513:Mice, SCID; D009368:Neoplasm Transplantation; D014183:Transplantation, Heterologous; D014407:Tumor Cells, Cultured / Q000276:immunology / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents